Tezspire Hits Phase 3 Goals in Eosinophilic Esophagitis, Expanding Amgen's Pipeline
AMGN sits 61% above its 52-week low of $269.77.
Summary
Amgen and AstraZeneca reported positive Phase 3 CROSSING trial results for Tezspire in eosinophilic esophagitis (EoE), a chronic inflammatory disease affecting over 470,000 U.S. patients. The drug met both co-primary endpoints—histologic remission and dysphagia improvement—with benefits sustained through 52 weeks. This is the first data readout for Tezspire in EoE, a new indication beyond its approved uses in severe asthma and nasal polyps. The results support a potential label expansion, though regulatory submission timing is not yet disclosed. Amgen shares were down 1.49% premarket, reflecting broader market conditions rather than the data itself. The company's Q2 beat and raised guidance provide a strong financial backdrop, but the FDA's proposed withdrawal of Tavneos and the unresolved IRS tax dispute remain key overhangs.
At the time of this announcement, AMGN was trading at $434.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $238.1B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.